loading
前日終値:
$3.85
開ける:
$4.3
24時間の取引高:
5.67M
Relative Volume:
23.44
時価総額:
$2.24M
収益:
$644.60K
当期純損益:
$-9.87M
株価収益率:
-0.0051
EPS:
-837.9618
ネットキャッシュフロー:
$-9.02M
1週間 パフォーマンス:
-13.17%
1か月 パフォーマンス:
-29.43%
6か月 パフォーマンス:
-92.76%
1年 パフォーマンス:
-93.95%
1日の値動き範囲:
Value
$4.18
$7.47
1週間の範囲:
Value
$3.50
$7.47
52週間の値動き範囲:
Value
$3.50
$220.25

Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile

Name
名前
Biodexa Pharmaceuticals Plc Adr
Name
セクター
Healthcare (1195)
Name
電話
-
Name
住所
-
Name
職員
16
Name
Twitter
Name
次回の収益日
2024-06-13
Name
最新のSEC提出書
Name
BDRX's Discussions on Twitter

BDRX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
BDRX 4.36 2.24M 644.60K -9.87M -9.02M -837.96
VRTX 449.99 115.43B 10.63B -479.80M -1.35B 13.33
REGN 747.10 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.88 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.29 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.68 24.89B 3.30B -501.07M 1.03B 11.54

Biodexa Pharmaceuticals Plc Adr (BDRX) 最新ニュース

pulisher
07:51 AM

Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic - Barchart

07:51 AM
pulisher
Nov 12, 2024

Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com

Nov 12, 2024
pulisher
Nov 07, 2024

Notice of General Meeting - StockTitan

Nov 07, 2024
pulisher
Nov 01, 2024

Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks

Nov 01, 2024
pulisher
Oct 29, 2024

BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Oct 29, 2024
pulisher
Oct 17, 2024

Biodexa reports promising glioblastoma trial results - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study - TipRanks

Oct 17, 2024
pulisher
Oct 17, 2024

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan

Oct 17, 2024
pulisher
Oct 16, 2024

Stock Surge: Biodexa Pharmaceuticals Plc ADR (BDRX) Closes at 5.01, Marking a -4.21 Increase/Decrease - The Dwinnex

Oct 16, 2024
pulisher
Oct 15, 2024

Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa secures Nasdaq listing extension - Investing.com

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa secures Nasdaq listing extension By Investing.com - Investing.com UK

Oct 15, 2024
pulisher
Oct 15, 2024

Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan

Oct 15, 2024
pulisher
Oct 05, 2024

Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - TipRanks

Oct 05, 2024
pulisher
Oct 04, 2024

Biodexa reports survival rates in glioblastoma study - Investing.com India

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa reports updated Phase 1 data from glioblastoma study (NASDAQ:BDRX) - Seeking Alpha

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa’s MTX110 Shows Promise in Brain Cancer Study - TipRanks

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa reports survival rates in glioblastoma study By Investing.com - Investing.com UK

Oct 04, 2024
pulisher
Oct 04, 2024

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - StockTitan

Oct 04, 2024
pulisher
Oct 03, 2024

Ratio Analysis: Unpacking Biodexa Pharmaceuticals Plc ADR (BDRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 03, 2024
pulisher
Oct 02, 2024

Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: A Year of Declines and Increases - The InvestChronicle

Oct 02, 2024
pulisher
Sep 26, 2024

Should investors be concerned about BDRX’s high price-to-sales ratio? - US Post News

Sep 26, 2024
pulisher
Sep 26, 2024

Interim results for the six months ended June 30, 2024 - StockTitan

Sep 26, 2024
pulisher
Sep 23, 2024

Market Watch Highlights: Biodexa Pharmaceuticals Plc ADR (BDRX) Ends on an Downturn Note at 0.29 - The Dwinnex

Sep 23, 2024
pulisher
Sep 19, 2024

Biodexa Pharmaceuticals announces ADR ratio change - Investing.com

Sep 19, 2024
pulisher
Sep 19, 2024

ADR Ratio Change - Markets Insider

Sep 19, 2024
pulisher
Sep 19, 2024

Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks

Sep 19, 2024
pulisher
Sep 16, 2024

Biodexa secures full access to cancer research grant - Investing.com

Sep 16, 2024
pulisher
Sep 04, 2024

BDRX Stock on the Rise: A Promising Investment - The InvestChronicle

Sep 04, 2024
pulisher
Sep 02, 2024

Financial Health Report: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Ratios Tell a Tale - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

Biodexa Pharmaceuticals Plc ADR (BDRX) produces promising results - US Post News

Sep 02, 2024
pulisher
Sep 02, 2024

Investors in cash trouble should check out Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News

Sep 02, 2024
pulisher
Aug 30, 2024

Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan

Aug 30, 2024
pulisher
Jul 24, 2024

Biodexa Pharmaceuticals Plc ADR (BDRX) is a good investment, but the stock may be undervalued - US Post News

Jul 24, 2024
pulisher
Jul 22, 2024

Balance Sheet Breakdown: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Jul 22, 2024
pulisher
Jul 19, 2024

Biodexa Pharmaceuticals sets $5 million offering - Investing.com

Jul 19, 2024
pulisher
Jul 17, 2024

Financial Metrics Check: Biodexa Pharmaceuticals Plc ADR (BDRX)’s Ratios for Trailing Twelve Months - The Dwinnex

Jul 17, 2024
pulisher
Jul 17, 2024

BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView

Jul 17, 2024
pulisher
Jul 16, 2024

Are Smart Investors Making the Right Decision? Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News

Jul 16, 2024
pulisher
Jul 16, 2024

Biodexa’s Diabetes Drug Enters Phase 2a Studies - TipRanks

Jul 16, 2024
pulisher
Jul 12, 2024

The time has not yet come to remove your chips from the table: Biodexa Pharmaceuticals Plc ADR (BDRX) - SETE News

Jul 12, 2024
pulisher
Jul 12, 2024

Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga

Jul 12, 2024
pulisher
Jul 11, 2024

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Benzinga

Jul 11, 2024
pulisher
Jul 11, 2024

eRapa shows promise in Phase 2 for FAP treatment, Biodexa reveals - Investing.com

Jul 11, 2024
pulisher
Jul 11, 2024

BDRX’s Stock Market Adventure: -73.47% YTD Growth Amidst Volatility - The InvestChronicle

Jul 11, 2024
pulisher
Jul 11, 2024

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI TractNow 12-Month Data - StockTitan

Jul 11, 2024
pulisher
Jul 10, 2024

Midatech Pharma PLC Announces Posting of Annual Report & Notice of AGM - Quantisnow

Jul 10, 2024
pulisher
Jul 10, 2024

Midatech Pharma PLC Announces Business Update - Quantisnow

Jul 10, 2024
pulisher
Jul 10, 2024

Midatech Pharma PLC Announces Fast Track Designation for MTX110 Development - Quantisnow

Jul 10, 2024
pulisher
Jul 10, 2024

Midatech Pharma PLC Announces IND Application for MTX110 Study in GBM Effective - Quantisnow

Jul 10, 2024

Biodexa Pharmaceuticals Plc Adr (BDRX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
大文字化:     |  ボリューム (24 時間):